![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background: To improve the prognostic evaluation of colorectal cancer requires new molecular markers. Cancerous inhibitor of protein phosphatase 2A (CIP2A) serves as an oncoprotein by targeting PP2A-mediated inhibition of c-Myc. A prognostic role for CIP2A has been demonstrated in gastric, lung, and tongue cancers. Methods: 863 consecutive colorectal cancer patients treated at Helsinki University Central Hospital in 1983-2001 were collected with 752 scored successfully for CIP2A immunohistochemical expression from tumor tissue microarrays. Associations with clinicopathologic variables and molecular markers were explored by the chi-square test, and the Kaplan-Meier method served for survival analysis. Results: CIP2A was overexpressed in 661 (87.9%) specimens. CIP2A overexpression was associated with tumor differentiation grade (p = 0.014), p53 immunopositivity (p = 0.042), EGFR immunopositivity (p = 0.007), and c-Myc nuclear immunopositivity (p = 0.018). In survival analysis, CIP2A failed to show any prognostic significance (p = 0.270, log-rank test). Conclusions: Overexpression of CIP2A in colorectal cancer patients may be an important step in colorectal carcinogenesis. Based on our findings, CIP2A shows no association with patient prognosis in colorectal cancer, but is associated with nuclear c-Myc.
Keywords: :
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
The CIP2A antibody was a kind gift from Dr. Edward K. Chan, University of Florida, USA. We thank Päivi Peltokangas, Tuire Koski, and Elina Aspiala for their excellent technical assistance.
Financial support from: Finska Läkaresällskapet (C.B. and C.H.), the Finnish Cancer Society (A.R.), the Finnish Dentists’ Association Apollonia (J.H.), the Dorothea Olivia Foundation (C.H.), Helsinki University Central Hospital Research Funds (A.R. and C.H.), the K. Albin Johansson Foundation (C.B.), the Karl Walter and Jarl Walter Perkléns minne Foundation (C.H.), Medicinska understödsföreningen Liv och Hälsa (C.H.), the Sigrid Jusélius Foundation (A.R. and C.H.), and the Waldemar von Frenckell Foundation (C.B.).
Note
Supplementary materias can be found at: http://www.landesbioscience.com/journals/cbt/article/18922/